Fresenius Delivers First US Biosimilar Approval
Kabi Receives Long-Awaited Nod From FDA For Stimufend Version Of Pegfilgrastim
Executive Summary
Fresenius Kabi has set out launch plans after receiving its first US biosimilar approval, for its Stimufend pegfilgrastim rival to Neulasta.